Cytosine Arabinoside With Daunorubicin or Adriamycin for Therapy of Acute Myelocytic Leukemia: A CALGB Study

A randomized comparison of the relative efficacy and toxicity of daunorubicin (DNR) at 30 or 45 mg/sq m or adriamycin (ADM) at 30 mg/sq m. given on the first 3 days of a 7-day continuous infusion of cytosine arabinoside (ara-C) at 100 mg/sq rn/day, shows the outcome to be dependent on anthracycline. dose. and patient age. DNR 45 is significantly better than DNR 30 or ADM 30 for inducing complete remissions (CR) in patients younger than 60 yr. (72%. 59%. 58 % CRs. respectively). DNA 30 is better than DNA 45 or ADM 30 for inducing CA in patients older than 60 T HE CANCER AND LEUKEMIA GROUP B has been involved in studies of acute myelocytic leukemia seriatim for 25 yr. Improved supportive care and eflective aggressive chemotherapy have resulted in an acceleration in progress in the past decade. Induc